Plain-English translation of NCT07715747 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase I trial is testing a new medication called in adults with advanced cancers that have spread to other parts of the body. The study will evaluate how safe the medication is, how your body processes it, and whether it helps slow or shrink tumors. Researchers will gradually increase the dose to find the best dose for future studies.
Many people with advanced cancers like ovarian, gastric, and endometrial cancer run out of standard treatment options. This trial exists to explore whether this new treatment could offer hope for patients whose cancers have stopped responding to existing therapies.
You likely qualify if…
You likely don't qualify if…
You would receive doses of the new medication, likely on a regular schedule at a medical center. The trial starts with lower doses and gradually increases them to find the safest, most effective level. You will have frequent visits for blood tests, imaging scans, and physical exams to monitor how you're responding and to watch for any side effects. The study will track how your body handles the medication and whether your tumors respond to treatment.
AI-generated summary from trial data · Oct 22, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
TJ Biopharma Co., Ltd.
Enrollment target
~128 participants
Started
August 2026
Primary completion
June 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lina Qin
TJ Biopharma Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.